Noticias de FATE_US

Noticias del mercado

Últimas noticias sobre FATE_US — 36 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: FATE_US ✕ 36 resultados
24/04/2026 FATE_US — Stock Titan
Fate Therapeutics (NASDAQ: FATE) sets 2026 proxy votes and 7M-share plan boost
23/04/2026 FATE_US — Barchart.com
iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ Emerging Therapies and Strong Innovation Momentum from Century Therapeutics, Fate Therapeutics | DelveInsight
23/04/2026 FATE_US — Stock Titan
Redmile (NASDAQ: FATE) corrects cash-settled swap reference price
22/04/2026 FATE_US — Stock Titan
Redmile reshapes Fate Therapeutics (NASDAQ: FATE) stake in exit filing
22/04/2026 FATE_US — Stock Titan
Redmile (NASDAQ: FATE) shifts stake to SPV in internal reorg
21/04/2026 FATE_US — ChartMill
FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE)
20/04/2026 FATE_US — tayninh.gov.vn
Fate Therapeutics (FATE) Stock: Why Market Expansion (Breakdown Watch) 2026-04-20 - Social Buzz
20/04/2026 FATE_US — laocai.gov.vn ES ← EN
Acciones de Fate Therapeutics (FATE): Por qué la expansión del mercado (observación de desgloses) 2026-04-20 - Social Buzz
20/04/2026 FATE_US — sonla.gov.vn ES ← EN
Acciones de Fate Therapeutics (FATE): Por qué la expansión del mercado (observación de desgloses) 2026-04-20 - Social Buzz
17/04/2026 FATE_US — Sahm
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at t

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at…

17/04/2026 FATE_US — MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by Brokerages
16/04/2026 FATE_US — Stock Titan
Fate cell therapy study targets blood cancers without chemo
16/04/2026 FATE_US — MarketScreener
Fate Therapeutics Announces Data Presentation Of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate For The Broad Treatment Of Hematological Malignancies And Autoimmune Diseases Without The Need For Conditioning Chemotherapy
16/04/2026 FATE_US — Yahoo Finance
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at t

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at…

15/04/2026 FATE_US — Yahoo Finance
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference
14/04/2026 FATE_US — openPR.com
NK Cell Therapy Market Is Booming Rapidly with Strong Demand
13/04/2026 FATE_US — tayninh.gov.vn
FATE Q4 2025 Earnings: Fate Therapeutics Inc. tops EPS estimates, reports no revenue - Social Buy Zones
10/04/2026 FATE_US — AD HOC NEWS
Fate Therapeutics Inc stock: Q2 2026 conferences signal active engagement
10/04/2026 FATE_US — haiphong.gov.vn
FATE Q4 2025 Earnings: Fate Therapeutics Inc. posts narrow EPS beat, no revenue reported - Elite Trading Signals
09/04/2026 FATE_US — GlobeNewswire
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

Página 1 de 2

keyboard_arrow_up